Zepbound’s sticker price looks alarming at first. But there are now multiple legitimate ways to pay far less — including a direct program from the manufacturer that cuts the cost by more than 70% without needing any insurance approval. This is the complete, current breakdown of what you’ll actually pay and how to get there.
Zepbound pricing has multiple layers, recent program changes, and a few important traps. Here are the direct answers to the questions that matter most before you scroll further.
- 1 What does Zepbound actually cost without insurance at the pharmacy? The full retail list price is approximately $1,086 per month — and that’s roughly $13,000 per year. This is the price most traditional pharmacies will quote if you walk in without a discount program. However, the list price is not what most cash-paying patients actually pay. GoodRx coupons can reduce it slightly (to around $980–$1,090 depending on the pharmacy), but the much larger savings come from Eli Lilly’s own programs — particularly the Self Pay Journey Program through LillyDirect, which brings the monthly cost to $299–$449 depending on your dose.
- 2 What is the cheapest legal way to get Zepbound without insurance? Eli Lilly’s Self Pay Journey Program through LillyDirect — starting at $299 per month for the 2.5 mg starting dose. This is a direct-to-patient program from the manufacturer that bypasses the pharmacy markup chain. You order through the LillyDirect platform with a valid prescription, and the medication ships to your home (or you can pick it up at a Walmart pharmacy). The pricing is $299 for 2.5 mg, $399 for 5 mg, and $449 for all doses from 7.5 mg through 15 mg — the highest dose carries the same price as the middle doses, which is a significant change from older pricing that many articles haven’t caught up with yet.
- 3 Does Medicare cover Zepbound for weight loss? Yes — but only through a temporary pilot program that began July 1, called the Medicare GLP-1 Bridge. Eligible Medicare Part D members pay a flat $50 per month for the Zepbound KwikPen (the multi-dose version — single-dose pens and vials are not covered under this program). To qualify, you generally need a BMI of 35 or higher, or a BMI of 27 or higher with weight-related health conditions. The program runs through December 31, 2027. This is confirmed by CMS (the Centers for Medicare and Medicaid Services) and is available through the official Medicare website.
- 4 Is there a Zepbound savings card, and who can use it? Yes — the Lilly Savings Card can bring the copay to as low as $25 per month for commercially insured patients whose plan covers Zepbound. There is also an uninsured version of the card with somewhat different terms. However, people on Medicare, Medicaid, TRICARE, or VA benefits are not eligible for the savings card under federal law. The card has annual benefit caps — the 2026 card limits savings to $1,300 per year — and it expires December 31 of the current year, requiring re-enrollment annually.
- 5 Is there a catch with the $449/month LillyDirect price for higher doses? Yes — the promotional price for doses 7.5 mg and above requires you to refill within 45 days of your previous delivery. If you miss that window, the price jumps back to the standard self-pay rates ($499–$1,049 depending on dose). Set a calendar reminder around day 30–35 after each delivery to protect your pricing. If you do miss it, you can re-enroll in the Self Pay Journey Program with your next order to get the promotional pricing back. The 2.5 mg and 5 mg doses don’t have this refill timing requirement.
- 6 Can I use the LillyDirect program while waiting for insurance approval? Yes — this is actually one of the most practical uses of the program. Prior authorization appeals for weight loss medications can take weeks or even months. Many patients start through LillyDirect at $299–$449 per month rather than delaying treatment. If your commercial insurance later approves coverage, you can switch from the self-pay program to using insurance plus the savings card, which can bring your cost down to $25 per month. The two programs are mutually exclusive on any given fill — you can’t combine them — but switching between them is straightforward.
- 7 What is Zepbound, and how is it different from Mounjaro? Zepbound and Mounjaro contain the exact same active ingredient — tirzepatide — but they are FDA-approved for different conditions. Mounjaro is approved for type 2 diabetes management. Zepbound received separate FDA approval for chronic weight management in adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related health condition, and also for moderate-to-severe obstructive sleep apnea in adults with obesity. The FDA prescribing information was last updated in April 2026. The drug is injected once weekly under the skin, and the maximum dose is 15 mg weekly.
- 8 Does commercial health insurance typically cover Zepbound for weight loss? Coverage is expanding but still inconsistent, and most plans require prior authorization. Even plans that do cover Zepbound typically require documentation of BMI, sometimes prior attempts at other weight loss methods, and a prescriber willing to complete the prior authorization forms. Some large pharmacy benefit managers have shifted their preferred GLP-1 — for example, the CVS Caremark formulary update in mid-2025 made Wegovy (semaglutide) the preferred choice on many plans it manages, which means patients on those plans may face more resistance getting Zepbound approved. Medicaid covers Zepbound for obesity in at least 13 states as of early 2026; coverage varies significantly by state.
There isn’t one Zepbound price — there are several, depending on which form you get, where you buy it, and whether you use a manufacturer program. Here is the current breakdown that reflects the most recent pricing changes.
For doses 7.5 mg through 15 mg, the $449 price is a promotional rate that depends on refilling within 45 days of your previous delivery. If you miss that window — say you travel, your prescription lapses, or you forget — the prices revert to the standard self-pay rates: $499 for 7.5 mg, $699 for 10 and 12.5 mg, and $1,049 for 15 mg. You can re-enroll in the Self Pay Journey Program with your next order to get back to $449. Set a recurring calendar alert around day 32 of each cycle to avoid this.
The primary LillyDirect fulfillment method is home delivery through partner pharmacies GiftHealth and Fuze Health. You order through the LillyDirect platform, a prescription is required, and the medication arrives at your door. Delivery timelines vary but are typically within a few business days. This is the most convenient channel for most patients and the one Eli Lilly has promoted most heavily.
Since November 2025, Walmart pharmacy locations can fill Zepbound vials through the LillyDirect self-pay program at the same pricing ($299–$449 depending on dose). This is a meaningful convenience addition for patients who prefer in-person pickup or want to avoid shipping delays. The KwikPen multi-dose version is also available through Amazon Pharmacy. Pricing is identical across all channels.
Per the official FDA prescribing information, Zepbound starts at 2.5 mg once weekly for four weeks. This starting dose is for treatment initiation only — it is not approved as a long-term maintenance dose. After four weeks, the dose increases to 5 mg weekly. From there, the prescriber may increase by 2.5 mg increments after at least four more weeks on each dose, based on how the patient is tolerating the medication and responding. The recommended maintenance doses for weight loss are 5 mg, 10 mg, or 15 mg weekly. The maximum approved dose is 15 mg weekly. For obstructive sleep apnea, the target maintenance doses are 10 mg or 15 mg weekly.
What this means for your wallet: Most patients spend their first one to two months at $299–$399 per month as they step through the starting doses. By the time they reach maintenance doses (typically 5 mg or higher), they’re looking at $399–$449 per month through LillyDirect — assuming they qualify for the self-pay program and refill on time.
This program represents the single biggest price break available for uninsured Zepbound patients. It’s also the one most people have heard about but don’t fully understand — here is the complete picture of how to use it and what the fine print means.
Step 1: Get a prescription. You need a valid prescription from any licensed U.S. prescriber for Zepbound for an FDA-approved use — either weight management or obstructive sleep apnea with obesity. The prescriber does not need to be enrolled in Medicare to write a prescription used for the self-pay program. Telehealth providers can also write the prescription.
Step 2: Go to LillyDirect. Visit the LillyDirect platform (lilly.com/lillydirect or the dedicated Zepbound savings page). There is no separate enrollment form — pricing applies automatically at checkout once your prescription reaches the LillyDirect pharmacy. You enter your prescription information, confirm your delivery address, and pay.
Step 3: Choose home delivery or Walmart pickup. Home delivery is handled through GiftHealth or Fuze Health. Walmart pharmacy pickup is available at participating locations. The KwikPen (multi-dose) version is also available through Amazon Pharmacy at the same self-pay pricing.
Step 4: Set a refill reminder. For the 7.5 mg dose and above, the $449 price requires refilling within 45 days of your previous delivery. Set a reminder around day 32–35 of each cycle. Miss the window and you pay the standard self-pay rate for that fill — then re-enroll to get back to the promotional price.
Important limitation: This is self-pay only. When using this program, you cannot bill insurance or seek reimbursement from any government benefit program for the same fill. Medicare and Medicaid patients can use LillyDirect on a cash basis — but nothing gets billed to their government plan.
The savings card is separate from the self-pay program and works differently. Understanding which one applies to your situation saves significant confusion at the pharmacy.
The savings card works as a secondary payer on top of your commercial insurance. Your insurance pays first; the savings card covers a portion of your remaining copay, bringing your out-of-pocket down to as little as $25 per fill. This is only available to patients whose commercial insurance plan covers Zepbound — if your plan doesn’t cover it, the card alone won’t get you to $25.
There is also an uninsured patient version of the savings card, which gives eligible uninsured patients access to the self-pay pricing ($299–$449) through a card-based mechanism rather than the LillyDirect portal. The end cost is essentially the same — the card just provides another enrollment pathway to the same pricing.
Who cannot use the savings card: Federal law prohibits manufacturer copay assistance cards for patients enrolled in government insurance programs — Medicare, Medicaid, TRICARE, the VA, or any federal or state government-funded healthcare. If you have Medicare or Medicaid, the savings card won’t apply; use LillyDirect self-pay or the Medicare GLP-1 Bridge instead. The 2026 card expires December 31 and requires re-enrollment at the start of each calendar year.
Most commercial insurance plans that cover Zepbound require prior authorization (PA) — a process where your prescriber submits documentation proving the medication is medically necessary for you. This typically includes your BMI, relevant health conditions, and sometimes documentation of prior weight loss attempts. PA reviews can take several business days to weeks. If denied, your prescriber can appeal. During this waiting period, many patients use LillyDirect self-pay ($299–$449/month) to begin treatment rather than wait. If coverage is later approved, switching to insurance plus the savings card reduces your cost further.
Significant changes have happened in how government programs handle Zepbound costs — and most people haven’t heard about the Medicare GLP-1 Bridge yet. Here is what’s confirmed from CMS and official government sources.
The Medicare GLP-1 Bridge is a temporary federal demonstration program confirmed by CMS that began July 1 and provides eligible Medicare Part D beneficiaries access to Zepbound for weight loss at a flat $50 monthly copay — regardless of dose. This is the first time Medicare has covered Zepbound (or any GLP-1) for weight loss purposes; federal law has prohibited this coverage since Part D launched in 2006. The program runs through December 31, 2027.
Critical detail: Only the Zepbound KwikPen formulation is covered under this program. The single-dose pens and the single-dose vials are explicitly excluded from the Medicare GLP-1 Bridge, per CMS’s official documentation. Make sure your prescription specifically states “Zepbound KwikPen” — if it’s written for pens or vials, the pharmacy cannot bill it through the program.
The $50 copay does not count toward your Part D deductible or the annual $2,100 out-of-pocket cap. An estimated 3.8 million Medicare beneficiaries may be eligible based on KFF analysis of enrollment data. To access the program, your doctor verifies eligibility based on BMI and health conditions, submits a prior authorization to Medicare, and writes the prescription for the KwikPen formulation.
Medicaid coverage for Zepbound for obesity varies significantly by state. As of early 2026, at least 13 states covered GLP-1 drugs like Zepbound for obesity under their Medicaid programs. A separate BALANCE model demonstration program launched in Medicaid in May 2026 and is testing expanded coverage through 2031. If Medicaid is your primary insurance, check your specific state’s Preferred Drug List (PDL) at your state Medicaid website — coverage rules, eligibility criteria, and required documentation differ substantially between states. Your prescriber can also appeal a denial on your behalf.
Because the LillyDirect self-pay program doesn’t bill any government program — you pay cash directly — Medicare and Medicaid patients can use it without violating the federal rules that block the savings card. If the Medicare GLP-1 Bridge isn’t available to you (wrong formulation, awaiting prior authorization, or the program doesn’t cover your specific situation), LillyDirect at $299–$449 per month remains an accessible option. Nothing is billed to Medicare or Medicaid, so no anti-kickback concerns apply.
Green signals an advantage in that category. Amber is moderate or conditional. Red marks a genuine limitation. Use this to identify which path fits your specific situation in under a minute.
| Option | Monthly Cost | Insurance Needed? | Who Qualifies | Catch / Condition | Best For |
|---|---|---|---|---|---|
| Retail List Price | ~$1,086 | No | Anyone with a prescription | No discount applied | No one — use a program instead |
| LillyDirect Self Pay Best No-Ins Option | $299–$449 | No | Anyone with a valid Rx; BMI eligibility | 45-day refill rule for doses ≥7.5 mg | Uninsured or waiting on PA |
| GoodRx Coupon | $980–$1,090 | No | Anyone with a prescription | Only 5–10% off list — minimal savings vs LillyDirect | Not recommended when LillyDirect available |
| Savings Card (with commercial ins.) | As low as $25 | Yes — must cover Zepbound | Commercial insurance that covers Zepbound; U.S. resident | $1,300 annual cap; no Medicare/Medicaid | Insured patients with coverage approved |
| Medicare GLP-1 Bridge NEW July 2026 | $50 | Medicare Part D required | Medicare Part D; BMI ≥35 or BMI ≥27 + conditions | KwikPen only; prior auth needed; through Dec 2027 | Medicare beneficiaries who qualify |
| Medicaid | Varies (often low copay) | Medicaid required | 13+ states cover for obesity as of early 2026 | Highly state-dependent; check your state PDL | Medicaid members in covered states |
| Commercial Insurance (no savings card) | $50–$150 typical copay | Yes — must cover Zepbound | Commercially insured with PA approval | Prior auth required; PA can be denied | Insured patients once PA approved |
| LillyDirect (miss refill window) | $499–$1,049 | No | Anyone — standard self-pay fallback | Standard price when 45-day refill window missed | Avoid by setting refill reminder |
Pricing reflects information current as of mid-2026. LillyDirect and savings card terms are subject to change by Eli Lilly. Medicare GLP-1 Bridge eligibility and terms confirmed by CMS. Always verify current pricing and eligibility at zepbound.lilly.com and with your healthcare provider before making any decisions.
The right path depends entirely on your insurance status, age, and where you are in the process. Here is the direct answer for each common situation.
Go to LillyDirect. The Self Pay Journey Program gives you access to brand-name Zepbound at $299 for the 2.5 mg starting dose, $399 for 5 mg, and $449 for all higher doses — without any insurance or prior authorization required. You need a valid prescription from any licensed U.S. prescriber. Order through lilly.com/lillydirect or ask your doctor if they can connect you through a telehealth partner. Avoid filling at a retail pharmacy at list price ($1,086) or using GoodRx — neither will get you close to what LillyDirect offers. Set a calendar reminder on day 32 of each cycle if you’re on a dose of 7.5 mg or above, to protect the promotional pricing.
Start LillyDirect while you appeal. Denial doesn’t mean the end — prior authorization denials for weight loss medications are commonly overturned on appeal, especially when your prescriber provides thorough documentation of your BMI, health conditions, and failed prior treatments. The appeal process can take weeks. Instead of waiting and delaying your treatment, use LillyDirect at $299–$449 per month in the meantime. If your appeal is approved and your insurance covers Zepbound, you can switch to filling through insurance plus the savings card (down to $25/month). The two channels don’t overlap — you simply switch when coverage kicks in.
For the first time, yes — if you meet the eligibility criteria. The Medicare GLP-1 Bridge that began July 1 covers the Zepbound KwikPen for eligible Part D members at a flat $50 per month. Talk to your doctor specifically about this program; they need to submit a prior authorization to Medicare and write the prescription for the KwikPen (not the vials or single-dose pens). If you don’t qualify for the Bridge or your prior auth is pending, LillyDirect self-pay at $299–$449 is your best alternative — you pay cash, nothing is billed to Medicare, and the federal rules that block savings cards don’t apply to pure cash transactions. Confirm your eligibility criteria with your doctor before enrolling in either pathway.
Call the member services number on the back of your insurance card and ask specifically: “Does my plan cover tirzepatide (Zepbound) for weight management?” Get the coverage tier, prior authorization requirements, and any step therapy requirements in writing. If coverage is confirmed, have your prescriber submit a prior authorization — your copay with insurance plus the savings card can drop to $25 per month. If your plan doesn’t cover it, check whether your employer’s HR department can escalate the issue — some large employers have added weight loss medication coverage in recent benefit cycles. In the meantime, use LillyDirect for uninterrupted access.
Schedule an appointment with your primary care physician or an obesity medicine specialist. Bring your weight history, any weight-related health conditions (high blood pressure, type 2 diabetes, sleep apnea, high cholesterol), and any previous weight loss attempts. These factors all strengthen the case for prescribing Zepbound and — when insurance is involved — for getting the prior authorization approved. If your regular doctor isn’t familiar with GLP-1 medications for weight loss, a telehealth provider specializing in metabolic health can often prescribe and connect you with the LillyDirect program directly. Many patients start this way and later transition to their primary care provider for ongoing management.
Tirzepatide is the active ingredient in both Zepbound and Mounjaro. Zepbound is the brand name for tirzepatide specifically approved by the FDA for chronic weight management (and obstructive sleep apnea in people with obesity). Mounjaro is the same molecule, approved specifically for type 2 diabetes management. They’re made by the same company (Eli Lilly) and work through the same mechanism — targeting both GLP-1 and GIP receptors to regulate appetite and blood sugar. The difference is FDA-approved indication, not pharmacology. Some patients with both diabetes and obesity receive Mounjaro and experience weight loss as a secondary benefit — that’s a conversation for your prescriber.
At list price with no programs: over $13,000 per year. Through LillyDirect at the starting 2.5 mg dose for a month, then escalating to maintenance at $449 for the rest of the year: roughly $5,100 annually. If your commercial insurance covers it with the savings card at $25 per fill: about $300 per year. Medicare GLP-1 Bridge at $50 per month: $600 per year. These numbers are why understanding the programs matters — the difference between paying list price and using LillyDirect is over $7,000 annually. The difference between LillyDirect and an approved insurance plan with the savings card is another $4,800 per year.
This is a critically important financial question, not just a medical one. Clinical trials — including the SURMOUNT-4 study published in JAMA — showed that patients who discontinued tirzepatide after 36 weeks of treatment regained approximately two-thirds of their weight loss within a year of stopping, compared to patients who continued the medication. This means Zepbound, like other GLP-1 medications, is generally intended as long-term treatment rather than a short course. That long-term commitment makes the ongoing monthly cost especially significant — and makes the sustainability of whichever pricing pathway you choose a central consideration before starting.
Generally yes, when Zepbound is prescribed for a qualifying medical condition — which obesity and obstructive sleep apnea are. HSA and FSA funds can typically be used for prescription medications prescribed by a licensed provider for a diagnosed medical condition. This means patients paying through LillyDirect self-pay can often use HSA or FSA funds to cover some or all of the monthly cost, effectively paying with pre-tax dollars. Confirm the specific rules with your HSA or FSA plan administrator, since guidelines and what counts as a qualifying expense can vary by plan.
The situation has changed significantly. The FDA declared tirzepatide no longer in shortage in October 2024, which effectively ended the widespread compounding of tirzepatide by 503B outsourcing facilities that was common during the shortage period. Some 503A pharmacies continue to compound tirzepatide under individual medical necessity documentation for specific patients, but the landscape is much more limited than it was. The FDA has continued signaling that compounded versions of drugs no longer on shortage are not appropriate as general alternatives. With LillyDirect now offering brand-name Zepbound at $299–$449 per month, the cost gap between branded and compounded has narrowed substantially — the risk profile of compounded products (unverified concentration, no large-scale safety data) is harder to justify when the legitimate option is meaningfully more affordable.
Eli Lilly also operates a patient assistance program for eligible patients with low income and no insurance coverage — separate from the Self Pay Journey Program. Eligibility is income-based and the application goes through the standard pharmaceutical patient assistance process. Additionally, nonprofit organizations including the Patient Advocate Foundation and the Healthwell Foundation provide financial assistance for medications including GLP-1 drugs for eligible patients. If you’re on Medicaid and your state doesn’t cover Zepbound yet, asking your prescriber to document medical necessity and submit a prior authorization can sometimes result in coverage approval even in states without blanket formulary coverage. Your prescriber can also escalate to the state’s PA exception process.
This page is for general informational purposes only and does not constitute medical or financial advice. Medication pricing, program terms, and coverage policies change frequently — verify all current prices and eligibility directly at zepbound.lilly.com, through your insurance provider, or at medicare.gov. The Medicare GLP-1 Bridge program terms are based on CMS official guidance current as of mid-2026; eligibility criteria and program availability may change. The Lilly Savings Card and Self Pay Journey Program terms, pricing, and annual caps are subject to change by Eli Lilly. Always consult a licensed healthcare provider before starting, changing, or stopping any medication. Zepbound (tirzepatide) is a prescription medication approved by the FDA and has associated risks and side effects — review the full prescribing information with your doctor.